| Biocon Limited |
70377010411 |
Aminocaproic Acid Oral Solution |
2022-10-24 |
1100.0000 |
Launch of a generic pharmaceutical. Pricing and supply offers made to large GPOs with purchasing decision authority for retail, wholesale, and specialty outlets. GPOs include Red Oak Sourcing, Walgreens Boots Alliance Development, ClarusONE Sourcing Services, and Econdisc. This product is priced at a discount of ~60% off the brand WAC. |
None |
69000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Biocon Limited |
70377010311 |
Aminocaproic Acid Tablets |
2022-10-24 |
1008.1100 |
Launch of a generic pharmaceutical. Pricing and supply offers made to large GPOs with purchasing decision authority for retail, wholesale, and specialty outlets. GPOs include Red Oak Sourcing, Walgreens Boots Alliance Development, ClarusONE Sourcing Services, and Econdisc. This product is priced at a discount of ~20% off the brand WAC. |
None |
20000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Biogen |
64406001901 |
Byooviz 0.5 mg (0.05 mL of 10 mg/mL solution) |
2022-07-01 |
1130.0000 |
BYOOVIZ will be marketed to Healthcare Professionals, Patients, Payers, and other appropriate audiences.
Further information can be found at:
https://www.biogen.com/content/dam/corporate/en_us/pdfs/BIOGEN_PricingPrinciplesInfographic_4-26-19.pdf |
None |
1000000 |
None |
None |
None |
None |
None |
None |
BYOOVIZ™ (ranibizumab-nuna), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV). The estimated number of patients provided in this report is based on 2021 prevalence estimates resulting from analyses of several data sources and publications. |
None |
| BioXcel Therapeutics, Inc. |
81092112001 |
Igalmi Sublingual Film 120 MCG 10 |
2022-07-01 |
1050.0000 |
BioXcel Therapeutics, Inc.consider multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply). Igalmi is an FDA approved treatment for Schizophrenia or bipolar I or II disorder in adults. which affects a number of patients in the US annually. BioXcel Therapeutics, Inc. approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment with BioXcel Therapeutics, Inc. products. |
None |
20625 |
1 |
None |
None |
None |
None |
None |
None |
None |
| BioXcel Therapeutics, Inc. |
81092118001 |
Igalmi Sublingual Film 180 MCG 10 |
2022-07-01 |
1050.0000 |
BioXcel Therapeutics, Inc.consider multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply). Igalmi is an FDA approved treatment for Schizophrenia or bipolar I or II disorder in adults. which affects a number of patients in the US annually. BioXcel Therapeutics, Inc. approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment with BioXcel Therapeutics, Inc. products. |
None |
8839 |
1 |
None |
None |
None |
None |
None |
None |
None |
| bluebird bio, Inc. |
73554311101 |
ZYNTEGLO (betibeglogene autotemcel) |
2022-10-01 |
2800000.0000 |
None |
1 |
1500 |
1 |
1 |
None |
None |
None |
None |
None |
None |
| bluebird bio, Inc. |
73554211101 |
SKYSONA is a cell suspension for intravenous infusion; a single dose of SKYSONA contains a minimum of 5.0 × 10^6 CD34+ cells/kg of body weight, suspended in a solution containing 5% dimethyl sulfoxide (DMSO) |
2022-12-01 |
3000000.0000 |
SKYSONA is an autologous hematopoietic stem cell-based gene therapy indicated to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). CALD is a rare, progressive, neurodegenerative disease that primarily affects young boys and causes irreversible, devastating neurologic decline, including major functional disabilities such as loss of communication, cortical blindness, requirement for tube feeding, total incontinence, wheelchair dependence, or complete loss of voluntary movement. Nearly half of patients who do not receive treatment die within five years of symptom onset. bluebird took this profound impact into consideration when pricing the therapy—weighing the therapy’s robust and sustained clinical benefit, quality of life improvements for patients and their families, cost savings to the system, and the overall impact on society. We are focused on timely access to this therapy for this patient population. |
None |
40 |
1 |
1 |
None |
None |
None |
None |
None |
None |
| Boehringer Ingelheim |
00597003510 |
SPEVIGO Vial 450mg/7.5mL (60mg/mL) 2ct |
2022-09-01 |
51133.0000 |
Specific Marketing and Pricing Plans for Spevigo® are not in the public domain or publicly available. Boehringer Ingelheim considers several factors in determining the price of our medicines. These factors include: the value of innovative medicines; cost effectiveness (meaning the economic value to patients given the effectiveness of the drug, compared to other drugs in the same class); investments made (including in research and development), manufacturing and other costs and the risks undertaken. Boehringer Ingelheim invests 20% of its net sales into research and development. |
None |
22816 |
1 |
1 |
None |
None |
None |
None |
Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available.
Note to Estimated Number of Patients: SPEVIGO® is the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults. It is estimated that 1 out of every 10,000 people have GPP. In the US, 22,816 patients are diagnosed with GPP, a fraction of which experience a GPP flare in a given year. |
None |
| Bristol Myers Squibb |
00003712511 |
OPDUALAG™ (240 mg and 80 mg/20 mL (12 mg and 4 mg/mL) Injection |
2022-03-18 |
13694.2700 |
We consider multiple factors when setting a list price for a medicine, including: (i) The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. (ii) Market and business considerations, including: Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; and Medical- and patient-service costs; this includes funding growing patient assistance programs; Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
180 |
None |
1 |
None |
None |
None |
None |
Comment regarding "Estimated Number of Patients" : 180 patients per month (forecast) |
None |
| Bristol Myers Squibb |
73625011311 |
Camzyos 10mg capsule, bottle of 30 |
2022-04-28 |
7356.1600 |
We consider multiple factors when setting a list price for a medicine, including: (i) The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. (ii) Market and business considerations, including: Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; and Medical- and patient-service costs; this includes funding growing patient assistance programs; Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
200 |
1 |
None |
2020-11-17 |
1310000000.0000 |
None |
Mavacamten is a heritage Myokardia investigational medication that BMS acquired in 2020 for $13.1 billion. Acquisition price of the individual drug is not publicly available |
Comment regarding "Estimated Number of Patients" : This is a first in class medication and the expectation is about 200 per month, subject to change. |
None |
| Bristol Myers Squibb |
73625011411 |
Camzyos 15mg capsule, bottle of 30 |
2022-04-28 |
7356.1600 |
We consider multiple factors when setting a list price for a medicine, including: (i) The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. (ii) Market and business considerations, including: Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; and Medical- and patient-service costs; this includes funding growing patient assistance programs; Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
200 |
1 |
None |
2020-11-17 |
1310000000.0000 |
None |
Mavacamten is a heritage Myokardia investigational medication that BMS acquired in 2020 for $13.1 billion. Acquisition price of the individual drug is not publicly available |
Comment regarding "Estimated Number of Patients" : This is a first in class medication and the expectation is about 200 per month, subject to change. |
None |
| Bristol Myers Squibb |
73625011111 |
Camzyos 2.5mg capsule, bottle of 30 |
2022-04-28 |
7356.1600 |
We consider multiple factors when setting a list price for a medicine, including: (i) The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. (ii) Market and business considerations, including: Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; and Medical- and patient-service costs; this includes funding growing patient assistance programs; Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
200 |
1 |
None |
2020-11-17 |
1310000000.0000 |
None |
Mavacamten is a heritage Myokardia investigational medication that BMS acquired in 2020 for $13.1 billion. Acquisition price of the individual drug is not publicly available |
Comment regarding "Estimated Number of Patients" : This is a first in class medication and the expectation is about 200 per month, subject to change. |
None |
| Bristol Myers Squibb |
73625011211 |
Camzyos 5mg capsule, bottle of 30 |
2022-04-28 |
7356.1600 |
We consider multiple factors when setting a list price for a medicine, including: (i) The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. (ii) Market and business considerations, including: Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; and Medical- and patient-service costs; this includes funding growing patient assistance programs; Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
200 |
1 |
None |
2020-11-17 |
1310000000.0000 |
None |
Mavacamten is a heritage Myokardia investigational medication that BMS acquired in 2020 for $13.1 billion. Acquisition price of the individual drug is not publicly available |
Comment regarding "Estimated Number of Patients" : This is a first in class medication and the expectation is about 200 per month, subject to change. |
None |
| Bristol Myers Squibb |
00003089511 |
SOTYKTU™ (deucravacitinib) for oral use, 6mg tablets; pink, round, biconvex, laser printed with “BMS 895” and “6 mg” on one side with no content on the other side |
2022-09-12 |
6164.3800 |
We consider multiple factors when setting a list price for a medicine, including: (i) The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. (ii) Market and business considerations, including: Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; and Medical- and patient-service costs; this includes funding growing patient assistance programs; Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
900 |
None |
None |
None |
None |
None |
None |
Comment regarding "Estimated Number of Patients" : Estimated 900 patients per month (forecast). However, BMS is unable to provide an exact number of patients who will be prescribed Sotyktu each month. |
None |